Chemistry:Talazoparib
 | |
| Clinical data | |
|---|---|
| Trade names | Talzenna |
| Other names | BMN-673 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618070 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | PARP inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 74% |
| Metabolism | Minimal metabolisation (<30%) |
| Elimination half-life | 90 (±58) hrs |
| Excretion | 69% in urine, 20% in feces |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H14F2N6O |
| Molar mass | 380.359 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase (PARP) inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations.[7] Talazoparib is similar to the first in class PARP inhibitor, olaparib.[8][9] It was approved in October 2018, in the United States and June 2019, in the European Union for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.[8][10][11][6]
In January 2024, the European Commission (EC) approved talazoparib in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults.[12]
Side effects
The most serious side effects in studies were related to the blood forming system and included anaemia (low red blood cell count), neutropenia (low neutrophil blood cell count) and thrombocytopenia (low platelet count). Serious forms of these conditions (grade 3 to 4) occurred in 39%, 21% and 15% of patients, respectively. Other adverse effects such as headache, nausea, hair loss and fatigue were mostly mild.[4]
Interactions
Combination with drugs that inhibit P-glycoprotein or BCRP may increase talazoparib concentrations in the body.[4]
Mechanism of action
Talazoparib acts as an inhibitor of poly ADP ribose polymerase (PARP) which aids in single strand DNA repair. Cells that have BRCA1/2 mutations are susceptible to the cytotoxic effects of PARP inhibitors because of an accumulation of DNA damage.[7] Talazoparib is theorized to have a higher potency than olaparib due to the additional mechanism of action called PARP trapping. PARP trapping is the mechanism of action where the PARP molecule is trapped on the DNA, which interferes with the cells ability to replicate. Talazoparib is found to be ~100 fold more efficient in PARP trapping than olaparib.[13] However, this increased potency may not translate directly to clinical effectiveness as many other factors must be considered.[9][13]
Society and culture
Economics
Talazoparib was developed by BioMarin Pharmaceutical Inc. and Medivation Inc. acquired all worldwide rights to talazoparib in August 2015.[14] Medivation acquired talazoparib for $410 million with additional payments of up to $160 million in royalties and milestones.[15] Pfizer acquired Medivation in 2016.
References
- ↑ "Talzenna Product information". 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98204.
- ↑ "Summary Basis of Decision (SBD) for Talzenna". 23 October 2014. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00458&lang=en.
- ↑ "Talzenna 0.25 mg hard capsules - Summary of Product Characteristics (SmPC)". 1 June 2021. https://www.medicines.org.uk/emc/product/10734/smpc.
- ↑ 4.0 4.1 4.2 "Talzenna- talazoparib capsule". 4 September 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2423edd-6d24-495c-aec1-c2f457f08d9a.
- ↑ "Talzenna- talazoparib capsule". 4 September 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13839d4f-6acf-4ffb-a128-79df59319273.
- ↑ 6.0 6.1 "Talzenna EPAR". 8 July 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna.
- ↑ 7.0 7.1 Medivation Inc.. "Talazoparib". http://www.medivation.com/research_development/talazoparib.
- ↑ 8.0 8.1 "FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 16 December 2019.
- ↑ 9.0 9.1 "PARP inhibitors: the race is on". British Journal of Cancer 114 (7): 713–5. March 2016. doi:10.1038/bjc.2016.67. PMID 27022824.
- ↑ "European Commission Approves Talzenna (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer" (Press release). Pfizer Inc. Archived from the original on 22 September 2020. Retrieved 23 June 2019.
- ↑ "Drug Approval Package: Talzenna (talazoparib)". 29 October 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000TOC.cfm.
- ↑ "Pfizer's Talzenna combination receives EC approval for metastatic prostate cancer" (in en). 2024-01-10. https://www.pmlive.com/pharma_news/pfizers_talzenna_combination_receives_ec_approval_for_metastatic_prostate_cancer_1506188.
- ↑ 13.0 13.1 "Trapping Poly(ADP-Ribose) Polymerase". The Journal of Pharmacology and Experimental Therapeutics 353 (3): 446–57. June 2015. doi:10.1124/jpet.114.222448. PMID 25758918.
- ↑ Biomarin (24 August 2015). "Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin" (Press release). Archived from the original on 5 February 2017. Retrieved 21 November 2016.
- ↑ Inman, Silus (25 August 2015). "Medivation Acquires BioMarin's PARP Inhibitor Talazoparib". http://www.onclive.com/web-exclusives/medivation-acquires-biomarins-parp-inhibitor-talazoparib?p=1.
 |  |
